GE, Affibody to develop PET imaging agentBy AuntMinnieEurope.com staff writers
June 5, 2012 -- GE Healthcare and Swedish biopharmaceutical company Affibody are collaborating on the development of a HER2-targeted PET imaging agent for patients with breast or gastric cancer.
Clinical trials are scheduled to begin later this year, according to the companies. These trials will investigate the confirmation of HER2 (human epidermal growth factor receptor 2) status in patients with breast cancer recurrence to determine if HER2 status changes over time. The studies will also monitor the therapy results of patients with metastatic breast cancer receiving anti-HER2 treatments and help resolve indeterminate HER2 tests.
GE, Karolinska explore cell therapy, May 22, 2012
GE hits European milestone for CT750 HD, May 18, 2012
GE imaging equipment arrives in London for Olympics, May 10, 2012
GE, Swedish firm collaborate on radiotracer program, April 19, 2012
GE's robotic C-arm for intervention prepares for action, March 16, 2012
Copyright © 2012 AuntMinnieEurope.com
Last Updated rm 6/5/2012 10:31:24 AM